JP2006527185A - 重症急性呼吸器症候群（ｓａｒｓ）の治療または予防するためのグリチルリチンまたはその誘導体 - Google Patents

重症急性呼吸器症候群（ｓａｒｓ）の治療または予防するためのグリチルリチンまたはその誘導体 Download PDF

Info

Publication number
JP2006527185A
JP2006527185A JP2006508438A JP2006508438A JP2006527185A JP 2006527185 A JP2006527185 A JP 2006527185A JP 2006508438 A JP2006508438 A JP 2006508438A JP 2006508438 A JP2006508438 A JP 2006508438A JP 2006527185 A JP2006527185 A JP 2006527185A
Authority
JP
Japan
Prior art keywords
glycyrrhizin
sars
derivative
infection
coronavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006508438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006527185A5 (enExample
Inventor
ジンドリッヒ・シナトル
ハンス・ヴィルヘルム・デーア
ゲロルト・ホーファー
マルティン・ミヒャエリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goethe Universitaet Frankfurt am Main
Original Assignee
Goethe Universitaet Frankfurt am Main
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goethe Universitaet Frankfurt am Main filed Critical Goethe Universitaet Frankfurt am Main
Publication of JP2006527185A publication Critical patent/JP2006527185A/ja
Publication of JP2006527185A5 publication Critical patent/JP2006527185A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2006508438A 2003-06-06 2004-06-07 重症急性呼吸器症候群（ｓａｒｓ）の治療または予防するためのグリチルリチンまたはその誘導体 Withdrawn JP2006527185A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47690803P 2003-06-06 2003-06-06
PCT/IB2004/002393 WO2004108122A1 (en) 2003-06-06 2004-06-07 Glycyrrhizin or derivatives thereof for treating or preventing severe acute respiratory syndrome (sars)

Publications (2)

Publication Number Publication Date
JP2006527185A true JP2006527185A (ja) 2006-11-30
JP2006527185A5 JP2006527185A5 (enExample) 2007-08-02

Family

ID=33511824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006508438A Withdrawn JP2006527185A (ja) 2003-06-06 2004-06-07 重症急性呼吸器症候群（ｓａｒｓ）の治療または予防するためのグリチルリチンまたはその誘導体

Country Status (7)

Country Link
US (1) US20070099855A1 (enExample)
EP (2) EP1660059A1 (enExample)
JP (1) JP2006527185A (enExample)
KR (1) KR20060025549A (enExample)
CN (1) CN1838947A (enExample)
CA (1) CA2527989A1 (enExample)
WO (1) WO2004108122A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532831A (ja) * 2009-07-09 2012-12-20 株式会社ミノファーゲン製薬 抗菌ペプチドの産生能復元剤としてのグリチルリチン
JP2022528813A (ja) * 2020-05-20 2022-06-16 シンテカバイオ インコーポレイティッド 二類重症急性呼吸器症候群コロナウイルス感染症の予防または治療用組成物
JP2023527053A (ja) * 2020-05-27 2023-06-26 アッテジェノ アクチエボラグ 治療使用のためのモノ及びビスニトロシル化アルキルポリオール

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2726606A1 (en) * 2011-06-28 2014-05-07 Leukocare Ag Novel stabilisation method for viruses or bacteria
RU2504397C1 (ru) * 2012-10-25 2014-01-20 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая фермент рибонуклеазу и глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия
US12447166B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
MY200875A (en) 2016-02-25 2024-01-20 Applied Biological Laboratories Inc Compositions and methods for protecting against airborne pathogens and irritants
CN106420695A (zh) * 2016-09-09 2017-02-22 南京农业大学 甘草素抗猪流行性腹泻病毒感染的应用
CN111084806B (zh) * 2020-02-13 2021-09-07 遵义医科大学 一种治疗或预防冠状病毒感染的药物组合物
CN111686253A (zh) * 2020-02-20 2020-09-22 田中民 一种预防和消杀冠状病毒的新方法
WO2021188504A1 (en) * 2020-03-18 2021-09-23 Flow Pharma, Inc. Injectable formulation of poly(lactic-co-glycolic (plga)) microspheres encapsulating siltuximab
US20230218548A1 (en) * 2020-03-19 2023-07-13 Eumentis Therapeutics, Inc. Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections
EP3888662A1 (en) * 2020-04-02 2021-10-06 Vossensteyn Compounds, compositions and devices for use in the treatment of coronavirus infections
EP4144363A4 (en) * 2020-04-27 2024-05-29 Guangzhou Century Clinical Research Co., Ltd Drug, food and application of anti-coronavirus infection
CN112135625B (zh) * 2020-04-27 2021-07-06 广州新创忆药物临床研究有限公司 一种预防或治疗covid-19新冠肺炎的药物及其应用
KR102169476B1 (ko) * 2020-05-20 2020-10-23 (주)신테카바이오 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물
WO2022051557A1 (en) * 2020-09-02 2022-03-10 Applied Biological Laboratories, Inc. Glycyrrhizin for the treatment or prophylaxis of viral infection
CN112457363B (zh) * 2020-11-23 2021-12-24 华南农业大学 一种马铃薯三糖齐墩果酸皂苷衍生物及其制备方法和应用
CN115192590B (zh) * 2021-04-13 2023-10-20 北京大学 甘草皂苷a3对新型冠状病毒刺突蛋白的抑制及其药物用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0312222B1 (en) * 1987-10-14 1992-08-05 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Treatment of diseases caused by viruses
US5156973A (en) * 1988-11-23 1992-10-20 Edward Shanbrom Antiviral blood sampling process and apparatus
JP3007665B2 (ja) * 1990-09-18 2000-02-07 日清製粉株式会社 コロナウィルス感染症の予防および治療剤ならびに消毒薬
RU2024542C1 (ru) * 1991-03-04 1994-12-15 Институт органической химии РАН ГЛИКОПЕПТИД β-ГЛИЦИРРИЗИНОВОЙ КИСЛОТЫ С МЕТИЛОВЫМ ЭФИРОМ ГЛИЦИЛ-L-ВАЛИНА, ПРОЯВЛЯЮЩИЙ АНТИ-СПИД-АКТИВНОСТЬ
US5356880A (en) * 1991-05-30 1994-10-18 Sanwa Kagaku Kenkyusho Co., Ltd. Glycyrrhetinic acid derivatives

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532831A (ja) * 2009-07-09 2012-12-20 株式会社ミノファーゲン製薬 抗菌ペプチドの産生能復元剤としてのグリチルリチン
JP2022528813A (ja) * 2020-05-20 2022-06-16 シンテカバイオ インコーポレイティッド 二類重症急性呼吸器症候群コロナウイルス感染症の予防または治療用組成物
JP7104449B2 (ja) 2020-05-20 2022-07-21 シンテカバイオ インコーポレイティッド 二類重症急性呼吸器症候群コロナウイルス感染症の予防または治療用組成物
JP2023527053A (ja) * 2020-05-27 2023-06-26 アッテジェノ アクチエボラグ 治療使用のためのモノ及びビスニトロシル化アルキルポリオール

Also Published As

Publication number Publication date
EP1719515A2 (en) 2006-11-08
US20070099855A1 (en) 2007-05-03
KR20060025549A (ko) 2006-03-21
EP1719515A3 (en) 2006-11-29
CA2527989A1 (en) 2004-12-16
EP1660059A1 (en) 2006-05-31
CN1838947A (zh) 2006-09-27
WO2004108122A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
US12351599B2 (en) Antiviral application of nucleoside analog or combination formulation containing nucleoside analog
JP2006527185A (ja) 重症急性呼吸器症候群（ｓａｒｓ）の治療または予防するためのグリチルリチンまたはその誘導体
AU2021331214B2 (en) Compounds and methods for treatment of viral infections
US20230100137A1 (en) Methods of treating and preventing alloantibody driven chronic graft versus host disease
ES3010487T3 (en) Vidofludimus for use in the treatment or prevention of viral diseases
EA016457B1 (ru) Аналог тиофена для лечения вирусной инфекции гепатита с
CN107281210B (zh) 阿奇霉素在抗冠状病毒感染中的应用
KR20250020476A (ko) Sars-cov-2를 포함한 바이러스성 감염을 치료하는 방법
CN111991401A (zh) 一种化合物在治疗SARS-CoV-2感染中的应用
CN111759851B (zh) 单宁酸在制备抗冠状病毒的药物方面的应用
JP2020196704A (ja) インフルエンザウイルス感染症またはコロナウイルス感染症の予防および／または治療剤
US20240002332A1 (en) Small Molecule Inhibitors of SARS-CoV-2 Infections
TW202517647A (zh) 用於治療病毒感染的化合物及方法
JP7293225B2 (ja) 組合せ製品を用いるｒｓｖの処置
US11883395B2 (en) Method of treating severe acute respiratory syndrome (SARS) virus infection by administering a protein disulfide isomerase (PDI) inhibitor
KR20010075202A (ko) 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제
CN110669028A (zh) 大象肠道来源的放线菌的丁烯酸内酯类化合物及其应用
CN102112461B (zh) 新型二芳基庚酮系化合物及其应用
HK40062780A (en) Vidofludimus for use in the treatment or prevention of viral diseases
HK40088088A (en) Antiviral application of nucleoside analog or combination formulation containing nucleoside analog
HK40032821B (en) Application of tannic acid in preparation of anti-coronavirus drugs
HK40032821A (en) Application of tannic acid in preparation of anti-coronavirus drugs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070605

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20071227